Xentria, Inc.
🇺🇸United States
Clinical Trials
12
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:8
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (66.7%)Phase 2
2 (16.7%)Phase 3
2 (16.7%)Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: US-Lantus®Drug: EU-Lantus®Drug: NKF-INS(G)
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT06627478
- Locations
- 🇿🇦
FARMOVS Clinical Research Organisation, Bloemfontein, South Africa
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT06504966
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: NKF-INS(A)Drug: EU-NovoRapid®Drug: US-NovoLog®
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06492226
- Locations
- 🇿🇦
Xentria Investigative Site, Bloemfontein, South Africa
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT06310824
- Locations
- 🇳🇱
Xentria Investigative Site, Groningen, Netherlands
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT06169397
- Locations
- 🇬🇧
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, England, United Kingdom
🇵🇱Xentria Investigative Site, Bielsk Podlaski, Poland
🇬🇧King's College Hospital NHS Foundation Trust, London, England, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found